CD274 and adenocarcinoma: This concerned six appraisals for PD-(L)1 inhibitors (TA428, TA520, TA600, TA683, TA705 and TA724), and appraisals of treatments targeting ALK (TA628 and TA670), EGFR (TA595), ROS1 (TA529), and indications adenocarcinoma (TA347) and NSCLC (TA403).